The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Development of the Princess Margaret Immune Oncology Prognostic Index (PM-IPI): A novel prognostic score for patients (pts) treated in immune oncology (IO) phase I (P1) trials.
 
Daphne Day
Travel, Accommodations, Expenses - Amgen; Sanofi
 
Anthony M. Joshua
Research Funding - Astellas Pharma (Inst)
 
Lisa Wang
No Relationships to Disclose
 
Albiruni R. Razak
Research Funding - MedImmune; Merck; Roche
 
Aaron Richard Hansen
No Relationships to Disclose
 
Natasha B. Leighl
Research Funding - Novartis (Inst)
 
Marcus O. Butler
Honoraria - Merck; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis
Expert Testimony - Merck
 
Anna Spreafico
No Relationships to Disclose
 
Lillian L. Siu
Leadership - Agios (I)
Stock and Other Ownership Interests - Agios (I); Entremed (I)
Consulting or Advisory Role - Boehringer Ingelheim; Daiichi Sankyo; Merck; Novartis (Inst); Oncoethix
Research Funding - Abraxis BioScience; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Celgene; Genentech/Roche; GlaxoSmithKline; Karyopharm Therapeutics; MedImmune; Merck; Novartis; Pfizer; Regeneron
 
Philippe L. Bedard
Consulting or Advisory Role - Genentech/Roche (Inst); Pfizer (Inst); Sanofi (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Oncothyreon (Inst); PTC Therapeutics (Inst); Sanofi (Inst); SERVIER (Inst); SignalChem (Inst)